Irvine-based Viseon Inc., an orthopedic spine technology company, has secured $18 million in Series B funding to bring its product into full commercialization.
“We have initiated limited commercial use of Viseon technology and early surgeon response has been very positive,” Chief Operations Officer Pete Davis said in a press release.
Viseon, which was spun out of Rebound Therapeutics in 2017, makes disposable, single-use cameras it calls Voyant that allows for real-time magnification of a surgery from the surgical instruments to in-room video monitors positioned above the patient.
“As fundamental as it may seem, enhanced real-time intraoperative visualization projected onto a large high-definition flat panel display will contribute toward clinical outcomes improvement, procedural efficiency, reduced risk of complications or staff involvement teaching opportunity and procedure expansion,” Chief Executive Jeffrey Valko said in a statement.
The company said its minimally invasive spine surgery devices will disrupt the way many procedures are performed, “including the displacement of the large, complex, capital equipment currently being used in operating rooms today.”
The company’s LinkedIn profile said it’s seeking a vice president of sales.
The Series B was co-led by New York-based Invus Opportunities, Greenwich, Conn.-based Wexford Capital LP and Irvine-based HBM-MedFocus. Viseon in 2017 received $5 million Series A funding from the same three investors.
